Steffen Zopf

Summary

Affiliation: University of Erlangen-Nuremberg
Country: Germany

Publications

  1. pmc Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
    Steffen Zopf
    Department of Medicine 1, University Hospital Erlangen, Ulmenweg 18, Erlangen, 91054, Germany
    BMC Cancer 12:386. 2012
  2. ncbi request reprint Localization of the polyol pathway in the human kidney
    Steffen Zopf
    Department of Internal Medicine 1, University of Erlangen Nuremberg, Erlangen, Germany
    Histol Histopathol 24:447-55. 2009
  3. doi request reprint Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation
    Steffen Zopf
    Medical Department 1, Hepatology and Gastroenterology, Friedrich Alexander University of Erlangen, Germany
    Scand J Gastroenterol 44:486-90. 2009
  4. ncbi request reprint The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells
    Matthias Ocker
    Department of Medicine I, University of Erlangen Nuernberg, Ulmenweg 18, 91054, Erlangen, Germany
    J Cancer Res Clin Oncol 131:385-94. 2005
  5. ncbi request reprint The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells
    Susanne Gahr
    Department of Medicine I, University Hospital Erlangen, Erlangen, Germany
    Int J Oncol 31:567-76. 2007
  6. ncbi request reprint Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo
    Steffen Zopf
    Department of Medicine 1, University Hospital Erlangen, D 91054, Erlangen, Germany
    Int J Oncol 31:1391-402. 2007
  7. ncbi request reprint Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy
    Matthias Ocker
    Department of Medicine I, Ulmenweg 18, Erlangen D 91054, Germany
    World J Gastroenterol 11:5521-4. 2005
  8. ncbi request reprint bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells
    Kinya Okamoto
    Department of Medicine 1, University Hospital Erlangen, Friedrich Alexander University Erlangen Nuernberg, Ulmenweg 18, D 91054 Erlangen, Germany
    J Cell Mol Med 11:349-61. 2007
  9. ncbi request reprint The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma
    Marion Ganslmayer
    Department of Internal Medicine I, University Erlangen Nuernberg, Ulmenweg 18, D 91054 Erlangen, Germany
    J Hepatol 40:952-6. 2004
  10. ncbi request reprint Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines
    Daniel Neureiter
    Department of Pathology, Friedrich Alexander University Erlangen Nurnberg, Erlangen, Germany
    Pancreatology 5:387-97. 2005

Collaborators

Detail Information

Publications15

  1. pmc Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
    Steffen Zopf
    Department of Medicine 1, University Hospital Erlangen, Ulmenweg 18, Erlangen, 91054, Germany
    BMC Cancer 12:386. 2012
    ..Inhibitors of protein and histone deacetylases (DACi) have been demonstrated to possess strong anti-tumor effects in HCC models...
  2. ncbi request reprint Localization of the polyol pathway in the human kidney
    Steffen Zopf
    Department of Internal Medicine 1, University of Erlangen Nuremberg, Erlangen, Germany
    Histol Histopathol 24:447-55. 2009
    ..Thus, the established rat model might well represent the situation in the human kidney, too...
  3. doi request reprint Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation
    Steffen Zopf
    Medical Department 1, Hepatology and Gastroenterology, Friedrich Alexander University of Erlangen, Germany
    Scand J Gastroenterol 44:486-90. 2009
    ..The aim of these investigations was to determine relapse rates in a retrospective analysis of 98 patients chronically infected with hepatitis C virus (HCV) genotype (GT) 1 in relation to the weight-based ribavirin dose...
  4. ncbi request reprint The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells
    Matthias Ocker
    Department of Medicine I, University of Erlangen Nuernberg, Ulmenweg 18, 91054, Erlangen, Germany
    J Cancer Res Clin Oncol 131:385-94. 2005
    ..The use of the triple combination could optimize treatment results in vivo and needs further evaluation...
  5. ncbi request reprint The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells
    Susanne Gahr
    Department of Medicine I, University Hospital Erlangen, Erlangen, Germany
    Int J Oncol 31:567-76. 2007
    ..Bax, an apoptosis inducing protein, which destabilizes the mitochondrial membrane potential, was increasingly expressed. Combination of TSA and gemcitabine shows promise for treatment of pancreatic cancer in vivo...
  6. ncbi request reprint Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo
    Steffen Zopf
    Department of Medicine 1, University Hospital Erlangen, D 91054, Erlangen, Germany
    Int J Oncol 31:1391-402. 2007
    ..0 on the extrinsic cell death pathway through activation of TRAIL and its signalling pathway indicate that A-423378.0 may be a potent new therapeutic compound for the treatment of advanced colorectal cancer...
  7. ncbi request reprint Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy
    Matthias Ocker
    Department of Medicine I, Ulmenweg 18, Erlangen D 91054, Germany
    World J Gastroenterol 11:5521-4. 2005
    ..To investigate if and to what extent antiviral therapy influenced a broad panel of quantitative testing of liver function (QTLF)...
  8. ncbi request reprint bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells
    Kinya Okamoto
    Department of Medicine 1, University Hospital Erlangen, Friedrich Alexander University Erlangen Nuernberg, Ulmenweg 18, D 91054 Erlangen, Germany
    J Cell Mol Med 11:349-61. 2007
    ..Our results demonstrate that siRNA-mediated silencing of anti-apoptotic bcl-2 enhances chemotherapy sensitivity in human pancreatic cancer cells in vitro and might lead to improved therapy responses in advanced stages of this disease...
  9. ncbi request reprint The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma
    Marion Ganslmayer
    Department of Internal Medicine I, University Erlangen Nuernberg, Ulmenweg 18, D 91054 Erlangen, Germany
    J Hepatol 40:952-6. 2004
    ..While an acyclic retinoid improved tumor-free survival after hepatoma resection, tamoxifen finally proved ineffective. Combination therapy of both agents has not been investigated in vitro and in vivo...
  10. ncbi request reprint Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines
    Daniel Neureiter
    Department of Pathology, Friedrich Alexander University Erlangen Nurnberg, Erlangen, Germany
    Pancreatology 5:387-97. 2005
    ..The aim of our study was to investigate the possibility of differentiation pathways of human pancreatic cancer cell lines in vivo...
  11. pmc Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma
    Marion Ganslmayer
    Medical Department 1, University Hospital Erlangen Nuernberg, Ulmenweg 18, 91054 Erlangen, Germany
    World J Gastroenterol 17:3623-9. 2011
    ..To evaluate the antitumoral effect of combined inhibitors of angiogenesis and histone deacetylases in an experimental rat hepatoma model...
  12. ncbi request reprint Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo
    Marion Ganslmayer
    Department of Medicine I, University Hospital Erlangen, Ulmenweg 18, D 91054 Erlangen, Germany
    Anticancer Res 32:5263-9. 2012
    ..Histone deacetylase (HDAC) inhibitors are promising antitumoral drugs. Currently there are no data regarding the comparison of different HDAC inhibitors on hepatoma cells...
  13. ncbi request reprint Potentiated anticancer effects on hepatoma cells by the retinoid adapalene
    Matthias Ocker
    Department of Internal Medicine I, University Erlangen Nuernberg, Ulmenweg 18, D 91054 Erlangen, Germany
    Cancer Lett 208:51-8. 2004
    ..3 in hepatoma cells. ADA inhibits hepatoma cell growth in vitro and is a powerful inducer of hepatoma cell apoptosis...
  14. doi request reprint Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis
    Tamar McHedlidze
    Medical Department 1, Friedrich Alexander University Erlangen Nuremberg, 91054 Erlangen, Germany
    Immunity 39:357-71. 2013
    ..Our data reveal key immunological networks implicated in hepatic fibrosis and support the concept of modulation of IL-33 bioactivity for therapeutic purposes. ..
  15. pmc Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report
    Susanne Gahr
    1 Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany
    J Cancer 3:158-65. 2012
    ....